| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | 0.33 | 6e-12 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.17 | 0.0007 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.15 | 0.005 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.008 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.076 | 0.009 |
| mRNA | BIBW2992 | FIMM | pan-cancer | AAC | 0.39 | 0.01 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.13 | 0.01 |